Find Therapeutics has secured CA$10 million (approximately $7.4 million) in funding to continue advancing tasronetide, its lead candidate for boosting myelin repair in people with multiple sclerosis (MS). The Series A extension financing round follows the completion of a Phase 1 trial in healthy volunteers, in which tasronetide was deemed safe and well tolerated. The […]
The post Find gets new funding for treatment to repair damaged myelin appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com